SCHEMBL21117867

SCHEMBL21117867

O=C1OC(=O)[C@H]2C3C=CC(CC3)C12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.48
KDM4E B2RXH2 1/20 0.48
GMNN O75496 1/20 0.48
PPM1B O75688 1/20 0.48
LMNA P02545 1/20 0.48
PPP1CC P36873 1/20 0.48
TFPI2 P48307 1/20 0.48
RAB9A P51151 1/20 0.48
PPP5C P53041 1/20 0.48
PPP1CA P62136 1/20 0.48
PMP22 Q01453 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TP53 P04637 1/20 0.48
CYP2D6 P10635 1/20 0.48
NFKB1 P19838 1/20 0.48
THPO P40225 1/20 0.48
POLB P06746 3/20 0.41
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
APEX1 P27695 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028639 1.00 TDP1 (0.48) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL10029224 1.00 TDP1 (0.48) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL2512784 1.00 TDP1 (0.48) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL351863 1.00 TDP1 (0.48) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL5833458 1.00 TDP1 (0.48) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL16199087 0.90 TDP1 (0.44) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL3199039 0.90 TDP1 (0.44) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL6519226 0.90 SMN1; SMN2 (0.44) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL6127457 0.90 TDP1 (0.44) TDP1KDM4EGMNNPPM1BLMNA
SCHEMBL18723992 0.90 TDP1 (0.44) TDP1KDM4EGMNNPPM1BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647693-B2 Inhibitors of influenza virus replication, application methods and uses thereof NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) 2020-05-12 US disclosed
US-20190194159-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647693-B2 Inhibitors of influenza virus replication, application methods and uses thereof EIF2AK2, POLRMT, SNRPE TDP1 2430/4885KDM4E 1222/4885GMNN 520/4885
US-20190194159-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF EIF2AK2, POLRMT, SNRPE TDP1 2430/4885KDM4E 1222/4885GMNN 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.